eligibility_summary
Eligibility: ≥8 kg, ≤21 y with recurrent/refractory solid tumor (RMS, Ewing, CNS, melanoma) after standard therapy, good PS, life expectancy >6 mo, resectable lesion for TIL plus measurable disease, AEs recovered, contraception/consent, adequate labs, organ, cardiac (LVEF ≥50% or LVFS >25%), pulmonary, caregiver/supportive care. Exclude: untreated symptomatic brain mets (non-CNS), uncontrolled illness/seizures, CNS bleed, active uveitis, psych/substance issues, immunodef, chronic lung disease, hypersensitivity, high risk/healing issues, recent other cancer, prior allogeneic transplant, steroids > replacement, live vaccine <28 d, active infection.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
manual_review_required
ai_summary
Trial: NCT06566092 (Phase 1). Intervention: LN-145/LN-144, an autologous tumor-infiltrating lymphocyte (TIL) product (biological/cellular therapy). A patient’s tumor is resected and TILs are expanded ex vivo, then reinfused. Mechanism of action: adoptive cell therapy that restores/amplifies antitumor immunity, TILs recognize patient-specific tumor antigens (including neoantigens) presented on MHC via their native TCRs, traffic to the tumor microenvironment, and kill tumor cells through cytotoxic pathways (perforin/granzymes) and cytokine secretion. Targets: malignant cells in solid tumors (RMS, EWS, primary CNS tumors, melanoma) and the immunosuppressive tumor microenvironment. Key effector cells: predominantly CD8+ cytotoxic T cells with supportive CD4+ T cells.